Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Krueger, J. Kunde, A. Hanschmann, R. Marre, N. Suttorp, T. Welte (Aachen, Hennigsdorf, Ulm, Berlin, Hannover, Germany). Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia. Eur Respir J 2008; 32: Suppl. 52, 1558

Member's Comments

No comment yet.

Related content which might interest you: Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Estimation of inflammatory process activity in community-acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Community-acquired pneumonia: severity and antibiotic treatments Source: ERS Course 2018 - Respiratory Infections Year: 2018 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 The tobacco-smoking influence on the community-acquired pneumonia course Source: Eur Respir J 2006; 28: Suppl. 50, 247s Year: 2006 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia Source: Eur Respir J 2016; 48: 1150-1159 Year: 2016 Frequency of side effects in antibiotic treatment for pneumonia Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Impact of neutrophil apoptosis on clinical outcomes in nonresponding community-acquired pneumonia Source: Annual Congress 2010 - Mechanisms of respiratory infections Year: 2010 Cytokine responses, microbial etiology and short-term outcome in community-acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017